0 53

Cited 0 times in

Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study

Authors
 Jongheon Jung  ;  Yoon Seok Choi  ;  Jae Hoon Lee  ;  Won Sik Lee  ;  Sung-Hyun Kim  ;  Yong Park  ;  Seung-Shin Lee  ;  Young Rok Do  ;  Jae-Cheol Jo  ;  Je-Jung Lee  ;  Jin Seok Kim  ;  Ho-Jin Shin  ;  Dong-Yeop Shin  ;  Sung-Soo Yoon  ;  Chang-Ki Min  ;  Kihyun Kim  ;  Hyeon-Seok Eom  ;  Korean Multiple Myeloma Working Party 
Citation
 INTERNATIONAL JOURNAL OF HEMATOLOGY, Vol.112(1) : 84-95, 2020-07 
Journal Title
 INTERNATIONAL JOURNAL OF HEMATOLOGY 
ISSN
 0925-5710 
Issue Date
2020-07
MeSH
Age Factors ; Aged ; Febrile Neutropenia / epidemiology ; Febrile Neutropenia / etiology ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Multiple Myeloma / therapy* ; Nausea / epidemiology ; Nausea / etiology ; Retrospective Studies ; Stem Cell Transplantation* / adverse effects ; Stomatitis / epidemiology ; Transplantation, Autologous ; Treatment Outcome
Keywords
Autologous ; Elderly ; Multiple myeloma ; Stem cell ; Transplantation
Abstract
Autologous stem cell transplantation (ASCT) is not frequently performed for elderly patients multiple myeloma (MM) in Korea, despite its being a standardized approach for young patients. Medical records of 150 patients from 15 Korean institutions who received ASCT at age ≥ 64 years were analyzed retrospectively. Patients included had symptomatic MM, and had received their first ASCT at age ≥ 64 following induction chemotherapy. The main outcome was the response after ASCT. Overall survival (OS) and progression-free survival (PFS) were also analyzed. Median time to ASCT was 6.3 months. Complete response plus stringent complete response rate increased from 36 (24.0%) to 105 (70.0%) after ASCT, and high-quality response (≥ very good partial response) increased from 96 (64.0%) to 125 (83.3%). With a median follow-up of 32.6 months after ASCT, 5-year OS and PFS were 59.7% and 22.8%, respectively. Febrile neutropenia occurred in 43.5%, and nausea (21.3%) and stomatitis (13.2%) were common grade 3-4 non-hematologic adverse events. Of 44 deaths, disease progression (n = 23) was the most common cause of mortality, followed by infection (n = 13). Treatment-related death occurred in four cases (2.7%). ASCT is an effective and safe option for elderly MM patients and is associated with superior clinical outcomes.
Full Text
https://link.springer.com/article/10.1007%2Fs12185-020-02869-y
DOI
10.1007/s12185-020-02869-y
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/180317
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links